Mr McLiesh has vast experience in commercializing pharmaceutical products internationally.As the former General Manager, Pharmaceuticals at CSL Limited, he was closely involved in the transition of CSL from government ownership through corporatisation to a highly successful listed company. While at CSL, Mr McLiesh brokered numerous in-licensing agreements with international companies enabling CSL to expand into new markets profitably.He has also been closely involved in a number of M&A transactions, the establishment of partnerships and collaborative relationships while he was the key professional to negotiate supply agreements for CSL's export products to international markets. Mr McLiesh was formerly a non executive director of Unilife Medical Solutions Ltd. His considerable experience in the international pharmaceutical industry benefits CLINUVEL's international strategies. In the latter stages of the development program Mr McLiesh is involved in formulating the commercial phase of CLINUVEL. Having been recognised for his strategic mindset and meticulous business execution, Dr Wolgen has brought to the Company his international finance experience and professional contacts to European capital markets. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. He held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising $86 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).Dr Wolgen holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen holds an MD from the University of Utrecht, the Netherlands.

 Pharmaceuticals, Medical devices